Cargando…

Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports

BACKGROUND: Plasma renin activity (PRA) is generally increased in patients with pheochromocytoma (PCC) due to low circulating plasma volume and activation of β-1 adrenergic receptor signaling. However, there has been no study on the aldosterone renin ratio (ARR) in patients with PCC. To elucidate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Tomoko, Fukuoka, Hidenori, Hosokawa, Yusei, Odake, Yukiko, Yoshida, Kenichi, Matsumoto, Ryusaku, Bando, Hironori, Okada, Yuko, Hirota, Yushi, Iguchi, Genzo, Ogawa, Wataru, Takahashi, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488748/
https://www.ncbi.nlm.nih.gov/pubmed/32917197
http://dx.doi.org/10.1186/s12902-020-00620-6
_version_ 1783581757249945600
author Yamada, Tomoko
Fukuoka, Hidenori
Hosokawa, Yusei
Odake, Yukiko
Yoshida, Kenichi
Matsumoto, Ryusaku
Bando, Hironori
Okada, Yuko
Hirota, Yushi
Iguchi, Genzo
Ogawa, Wataru
Takahashi, Yutaka
author_facet Yamada, Tomoko
Fukuoka, Hidenori
Hosokawa, Yusei
Odake, Yukiko
Yoshida, Kenichi
Matsumoto, Ryusaku
Bando, Hironori
Okada, Yuko
Hirota, Yushi
Iguchi, Genzo
Ogawa, Wataru
Takahashi, Yutaka
author_sort Yamada, Tomoko
collection PubMed
description BACKGROUND: Plasma renin activity (PRA) is generally increased in patients with pheochromocytoma (PCC) due to low circulating plasma volume and activation of β-1 adrenergic receptor signaling. However, there has been no study on the aldosterone renin ratio (ARR) in patients with PCC. To elucidate the issue, this study aimed to determine the PRA, plasma aldosterone concentration (PAC), and ARR in patients with PCC and compare them with those in patients with subclinical Cushing’s syndrome (SCS) and non-functioning adrenal adenoma (NFA). METHODS: In this retrospective single-center, cross-sectional study, 67 consecutive patients with adrenal tumors (PCC (n = 18), SCS (n = 18), and NFA (n = 31)) diagnosed at Kobe University Hospital between 2008 and 2014 were enrolled. RESULTS: PRA was significantly higher in patients with PCC than in those with SCS and NFA (2.1 (1.3 ~ 2.8) vs. 0.7 (0.5 ~ 1.8) and 0.9 (0.6 ~ 1.4) ng/mL/h; p = 0.018 and p = 0.025). Although PACs were comparable among the three groups, ARR was significantly lower in patients with PCC than in those with SCS and NFA (70.5 (45.5 ~ 79.5) vs. 156.0 (92.9 ~ 194.5) and 114.9 (90.1 ~ 153.4); p = 0.001 and p < 0.001). Receiver operating characteristic curve analysis demonstrated that, in differentiating PCC from NFA, PRA > 1.55 ng/mL/h showed a sensitivity of 70.0% and specificity of 80.6%. Interestingly, ARR < 95.4 showed a sensitivity of 83.3% and specificity of 86.7%, which were higher than those in PRA. CONCLUSIONS: ARR decreased in patients with PCC, which was a more sensitive marker than PRA. Further study is necessary to understand the usefulness of this convenient marker in the detection of PCC. TRIAL REGISTRATION: This study was not registered because of the retrospective analysis.
format Online
Article
Text
id pubmed-7488748
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74887482020-09-16 Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports Yamada, Tomoko Fukuoka, Hidenori Hosokawa, Yusei Odake, Yukiko Yoshida, Kenichi Matsumoto, Ryusaku Bando, Hironori Okada, Yuko Hirota, Yushi Iguchi, Genzo Ogawa, Wataru Takahashi, Yutaka BMC Endocr Disord Research Article BACKGROUND: Plasma renin activity (PRA) is generally increased in patients with pheochromocytoma (PCC) due to low circulating plasma volume and activation of β-1 adrenergic receptor signaling. However, there has been no study on the aldosterone renin ratio (ARR) in patients with PCC. To elucidate the issue, this study aimed to determine the PRA, plasma aldosterone concentration (PAC), and ARR in patients with PCC and compare them with those in patients with subclinical Cushing’s syndrome (SCS) and non-functioning adrenal adenoma (NFA). METHODS: In this retrospective single-center, cross-sectional study, 67 consecutive patients with adrenal tumors (PCC (n = 18), SCS (n = 18), and NFA (n = 31)) diagnosed at Kobe University Hospital between 2008 and 2014 were enrolled. RESULTS: PRA was significantly higher in patients with PCC than in those with SCS and NFA (2.1 (1.3 ~ 2.8) vs. 0.7 (0.5 ~ 1.8) and 0.9 (0.6 ~ 1.4) ng/mL/h; p = 0.018 and p = 0.025). Although PACs were comparable among the three groups, ARR was significantly lower in patients with PCC than in those with SCS and NFA (70.5 (45.5 ~ 79.5) vs. 156.0 (92.9 ~ 194.5) and 114.9 (90.1 ~ 153.4); p = 0.001 and p < 0.001). Receiver operating characteristic curve analysis demonstrated that, in differentiating PCC from NFA, PRA > 1.55 ng/mL/h showed a sensitivity of 70.0% and specificity of 80.6%. Interestingly, ARR < 95.4 showed a sensitivity of 83.3% and specificity of 86.7%, which were higher than those in PRA. CONCLUSIONS: ARR decreased in patients with PCC, which was a more sensitive marker than PRA. Further study is necessary to understand the usefulness of this convenient marker in the detection of PCC. TRIAL REGISTRATION: This study was not registered because of the retrospective analysis. BioMed Central 2020-09-11 /pmc/articles/PMC7488748/ /pubmed/32917197 http://dx.doi.org/10.1186/s12902-020-00620-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Yamada, Tomoko
Fukuoka, Hidenori
Hosokawa, Yusei
Odake, Yukiko
Yoshida, Kenichi
Matsumoto, Ryusaku
Bando, Hironori
Okada, Yuko
Hirota, Yushi
Iguchi, Genzo
Ogawa, Wataru
Takahashi, Yutaka
Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports
title Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports
title_full Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports
title_fullStr Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports
title_full_unstemmed Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports
title_short Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports
title_sort patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488748/
https://www.ncbi.nlm.nih.gov/pubmed/32917197
http://dx.doi.org/10.1186/s12902-020-00620-6
work_keys_str_mv AT yamadatomoko patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports
AT fukuokahidenori patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports
AT hosokawayusei patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports
AT odakeyukiko patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports
AT yoshidakenichi patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports
AT matsumotoryusaku patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports
AT bandohironori patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports
AT okadayuko patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports
AT hirotayushi patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports
AT iguchigenzo patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports
AT ogawawataru patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports
AT takahashiyutaka patientswithpheochromocytomaexhibitlowaldosteronereninratiopreliminaryreports